RxDoctor Payments Data

Mark Harris, MD

Pain Medicine · Meridian, IDNPI 1790825842

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 25.2% of the total. That places this record below the midpoint for pain medicine clinicians in ID, where the typical reported total is $4,838.

$1,189in general payments, 2019–2025

Across 47 payments — averaging $25.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$299
  • Vertos Medical, Inc.$162
  • E.r. Squibb & Sons, L.L.C.$134
  • Painteq LLC$134
  • Boston Scientific$80
  • Teva Pharmaceuticals USA, Inc.$80
  • plus $300 from 10 others

What the payments were for

  • Food & beverage$1,16898%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,189 in reported general payments places this provider in the 20th percentile of 32 pain medicine providers in Idaho.

See all pain medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$158,567
Medicare patients
298
Services billed
2,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine209$67,530
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,408$48,540
OxycontinOxycodone Hcl28$15,755
Gabapentin864$14,286
BelbucaBuprenorphine Hcl12$11,779
Oxycodone Hcl389$9,757
Baclofen419$8,667
Tizanidine Hcl583$7,346
Morphine Sulfate ErMorphine Sulfate227$6,577
SavellaMilnacipran Hcl13$6,361
Naloxone Hcl91$6,155
Pregabalin205$5,962
Lidocaine56$5,579
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen124$5,081
Duloxetine Hcl160$3,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$21$69,396279 claims
AbbVieSavella$299$6,36113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 32 pain medicine providers in Idaho.

Other pain medicine in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →